mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys

被引:103
作者
Samadi, Pershia [2 ]
Gregoire, Laurent
Morissette, Marc
Calon, Frederic [2 ]
Tahar, Abdallah Hadj [3 ]
Dridi, Mehdi [2 ]
Belanger, Nancy [3 ]
Meltzer, Leonard T. [4 ]
Bedard, Paul J. [3 ,5 ]
Di Paolo, Therese [1 ,2 ]
机构
[1] Univ Laval, Med Ctr, CHUL, Mol Endocrinol & Oncol Res Ctr, Quebec City, PQ G1V 4G2, Canada
[2] Univ Laval, Fac Pharm, Quebec City, PQ G1V 4G2, Canada
[3] Univ Laval, Med Ctr, Neurosci Res Ctr, Quebec City, PQ G1V 4G2, Canada
[4] Ann Arbor Labs, Pfizer Global Res & Dev, Ann Arbor, MI USA
[5] Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada
基金
加拿大健康研究院;
关键词
basal ganglia; Parkinson's disease; dyskinesias; mGluR5; NMDA antagonist; cabergoline;
D O I
10.1016/j.neurobiolaging.2007.02.005
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Modulation of excessive glutamatergic transmission within the basal ganglia is considered as an alternative approach to reduce L-Dopa-induced dyskinesias (LIDs) in Parkinson's disease (PD). In this study receptor binding autoradiography of [3 H]MPEP, a metabotropic glutamate receptor 5 (mGluR5) selective radioligand, was used to investigate possible changes in mGluR5 in the basal ganglia Of L-Dopa-treated 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared to animals in which LIDs was prevented by adjunct treatments. LIDs were associated with an increase of mGluR5 specific binding in the posterior putamen and pallidum (+41 % and +56%) compared to controls. By contrast, prevention of dyskinesias was associated with an important decrease of mGluR5 specific binding in these areas (-37% and -48%) compared with dyskinetic animals. Moreover, an upregulation (+34%) of mGluR5 receptor binding was seen in the anterior caudate nucleus of saline treated MPTP monkeys. This study is the first to provide evidence that enhanced mGluR5 specific binding in the posterior putamen and pallidum may contribute to the pathogenesis of LIDs in PD. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1040 / 1051
页数:12
相关论文
共 61 条
[1]   NMDA-induced potentiation of mGluR5 is mediated by activation of protein phosphatase 2B/calcineurin [J].
Alagarsamy, S ;
Saugstad, J ;
Warren, L ;
Mansuy, IM ;
Gereau, RW ;
Conn, PJ .
NEUROPHARMACOLOGY, 2005, 49 :135-145
[2]  
Andiné P, 1999, J PHARMACOL EXP THER, V290, P1393
[3]   Heterosynaptic dopamine neurotransmission selects sets of corticostriatal terminals [J].
Bamford, NS ;
Zhang, H ;
Schmitz, Y ;
Wu, NP ;
Cepeda, C ;
Levine, MS ;
Schmauss, C ;
Zakharenko, SS ;
Zablow, L ;
Sulzer, D .
NEURON, 2004, 42 (04) :653-663
[4]   Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice [J].
Battaglia, G ;
Busceti, CL ;
Molinaro, G ;
Biagioni, F ;
Storto, M ;
Fornai, F ;
Nicoletti, F ;
Bruno, V .
JOURNAL OF NEUROSCIENCE, 2004, 24 (04) :828-835
[5]   Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in Parkinsonian monkeys [J].
Bélanger, N ;
Grégoire, L ;
Tahar, AH ;
Bédard, PJ .
MOVEMENT DISORDERS, 2003, 18 (12) :1436-1441
[6]  
Blanchet PJ, 1999, J PHARMACOL EXP THER, V290, P1034
[7]   Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease [J].
Blanchet, PJ ;
Papa, SM ;
Metman, LV ;
Mouradian, MM ;
Chase, TN .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 1997, 21 (04) :447-453
[8]  
BLANCHET PJ, 1995, J PHARMACOL EXP THER, V272, P854
[9]  
Breysse N, 2003, J NEUROSCI, V23, P8302
[10]  
Breysse N, 2002, J NEUROSCI, V22, P5669